Nalazite se na CroRIS probnoj okolini. Ovdje evidentirani podaci neće biti pohranjeni u Informacijskom sustavu znanosti RH. Ako je ovo greška, CroRIS produkcijskoj okolini moguće je pristupi putem poveznice www.croris.hr
izvor podataka: crosbi

Interaction between <i>ABCG2 421C>A</i> polymorphism and valproate in their effects on steady-state disposition of lamotrigine in adults with epilepsy (CROSBI ID 320918)

Prilog u časopisu | izvorni znanstveni rad | međunarodna recenzija

Klarica Domjanović, Iva ; Lovrić, Mila ; Trkulja, Vladimir ; Petelin-Gadže, Željka ; Ganoci, Lana ; Čajić, Ivana ; Božina, Nada Interaction between <i>ABCG2 421C>A</i> polymorphism and valproate in their effects on steady-state disposition of lamotrigine in adults with epilepsy // British journal of clinical pharmacology, 84 (2018), 9; 2106-2119. doi: 10.1111/bcp.13646

Podaci o odgovornosti

Klarica Domjanović, Iva ; Lovrić, Mila ; Trkulja, Vladimir ; Petelin-Gadže, Željka ; Ganoci, Lana ; Čajić, Ivana ; Božina, Nada

engleski

Interaction between <i>ABCG2 421C>A</i> polymorphism and valproate in their effects on steady-state disposition of lamotrigine in adults with epilepsy

Aims: To investigate the impact of glucuronidation enzyme (UGT1A4*3 142T>G, UGT1A4*2 70C>A, UGT2B7 -161C>T) and transporter (MDR1/ABCB1 1236C>T, ABCG2 421C>A) polymorphisms on steady-state disposition of lamotrigine and on the lamotrigine- valproate interaction. Methods: Adults with epilepsy on lamotrigine monotherapy (n = 131) or lamotrigine + valproate treatment (n = 74) were genotyped and steady-state lamotrigine and valproate morning troughs were determined as a part of routine therapeutic drug monitoring. Results: No effect of UGT and MDR1/ABCB1 polymorphisms was observed. In the entire cohort, ABCG2 421A allele had no effect however an interaction between the variant allele and valproate was observed: (i) in lamotrigine-only patients, variant allele (vs. wild type homozygosity) was independently (adjustments: age, sex, body mass index, lamotrigine dose, other polymorphisms) associated with mildly lower lamotrigine troughs [geometric means ratio (GMR) = 0.76, 95% confidence interval (CI) 0.59-0.98], whereas in lamotrigine + valproate patients it was associated with higher troughs (GMR = 1.72, 95%CI 1.14-2.62) ; (ii) valproate cotreatment was overall associated with markedly higher troughs vs. lamotrigine monotherapy (GMR = 3.49, 95%CI 2.73- 4.44), but more so in variant allele carriers (GMR = 5.24, 95%CI 3.38-8.15) than in wild type homozygotes (GMR = 2.32, 95%CI 1.89- 2.83) ; (iii) variant allele effects in two treatment subsets and valproate effects in two genotype subsets differed by 2.36-fold (95%CI 1.39-3.67) ; (iv) increase in lamotrigine troughs associated with increasing valproate troughs was greater in variant allele carriers than in wild type homozygotes, i.e. variant allele effect increased with increasing valproate troughs. Conclusion: This study is first to indicate a potentially relevant interaction between ABCG2 421C>A polymorphism and valproate in their effects on lamotrigine disposition.

clinical pharmacology ; drug interactions ; drug transporter ; genetics and pharmacogenetic ; pharmacogenomics ; pharmacokinetics

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

Podaci o izdanju

84 (9)

2018.

2106-2119

objavljeno

0306-5251

10.1111/bcp.13646

Povezanost rada

Kliničke medicinske znanosti

Poveznice
Indeksiranost